Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

GVV858

Small molecule · developed by Novartis Pharmaceuticals

Phase 1/2 Most advanced trial
NVS Developer

What is GVV858?

GVV858 is a drug studied in advanced HR+/HER2- breast cancer, advanced CCNE1-amplified solid tumors, and metastatic castration-resistant prostate cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Therapy area
Oncology
Developer
Novartis Pharmaceuticals (NVS)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2

Conditions studied

Advanced CCNE1-amplified Solid TumorsAdvanced HR+/HER2- Breast CancerMetastatic Castration-resistant Prostate Cancer

More from Novartis Pharmaceuticals

Follow NVS, the company behind GVV858

See NVS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

NVS catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.